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Edited by Jesus AvilaAbstract We employed transgenic mice overexpressing beta-
cellulin (BTC) to study its eﬀects in the gut. BTC stimulated
crypt cell proliferation and markedly increased intestinal size,
while the crypt-villus architecture was preserved. Introduction
of a dominant negative epidermal growth factor receptor
(EGFR) completely abolished the intestinal hyperplasia. BTC in-
creased polyp multiplicity but did not change the mean size or the
histological quality of intestinal polyps in Apc+/Min mice. Analy-
sis of intact and cleaved caspase-3 levels indicated that BTC has
anti-apoptotic eﬀects in the intestinal epithelium. We conclude
that increased BTC levels support the survival of nascent adeno-
mas in Apc+/Min mice, resulting in a larger total polyp number at
later stages.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The epidermal growth factor receptor (EGFR, ERBB1) is of
essential importance for the homeostasis of epithelial tissues.
Canonical EGFR activation involves ligand-induced homodi-
merization or heterodimerization with the related ERBB2
(neu), ERBB3 or ERBB4 receptors, with the formed dimers
inducing potent intracellular signaling [1]. The EGFR ligands
include amphiregulin (AREG), betacellulin (BTC), epidermal
growth factor (EGF), epigen (EPGN), epiregulin (EREG),
heparin-binding EGF-like growth factor (HBEGF) and trans-
forming growth factor alpha (TGFA) [2].
The EGFR and its ligands are widely expressed in the intes-
tinal epithelium and play important roles in the regulation ofAbbreviations: AREG, amphiregulin; BTC, betacellulin; DSS, dextran
sulfate sodium; EGF, epidermal growth factor; EGFR, EGF receptor;
EPGN, epigen; EREG, epiregulin; HBEGF, heparin-binding EGF-like
growth factor; TGFA, transforming growth factor alpha; BTC-tg,
betacellulin transgenic; PFA, Paraformaldehyde; WT, wild-type
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doi:10.1016/j.febslet.2008.07.026gastrointestinal physiology and pathology [3]. While targeted
inactivation of the Egfr gene in mice results in strain-depen-
dent lethality, favorable genetic backgrounds allow develop-
ment to the early postnatal period. In these mice, although
the intestinal crypt architecture and cell lineages are preserved,
villi are reduced in size and number, and cell proliferation is
decreased [4,5]. In contrast, mutations in the genes encoding
the EGFR ligands have resulted in much milder phenotypes.
Mice lacking TGFA [6] or EREG [7] show solely an increased
susceptibility to intestinal damage caused by oral administra-
tion of dextran sulfate sodium (DSS), and even triple knockout
mice lacking EGF, TGFA and AREG show only minor de-
fects in gastrointestinal development [8]. The eﬀects elicited
by overexpressing EGFR ligands in the intestinal epithelium
are also relatively mild: EGF transgenic mice show enhanced
intestinal adaptation after small bowel resection [9], while
TGFA overproduction resulted in increased crypt cell prolifer-
ation [10] and protected transgenic mice from DSS-induced
colitis [11].
The levels of EGFR or its ligands are often increased in tu-
mors as compared to the unaﬀected surrounding tissue [12],
and deregulation of EGFR signaling is frequently associated
with tumorigenesis [13,14]. For instance, the hypomorphic al-
lele Egfrwa2 [15] and the antimorphic allele Egfrwa5 reduce the
multiplicity of adenomas in the Apc+/Min mouse model of
familial adenomatous polyposis. However, treatment of
Apc+/Min mice with recombinant EGF over 4 weeks failed to
increase polyp number [16].
Betacellulin is widely expressed in the gastrointestinal tract
[8,17]. Infusion of BTC into rats resulted in a moderate in-
crease in intestinal growth, but, surprisingly, no increase in cell
proliferation was detected [18]. We recently generated trans-
genic mouse lines producing higher-than-normal levels of this
EGFR ligand under control of the b-actin promoter [19]. In
the initial analysis of these lines we observed transgene expres-
sion in the intestine, but overt eﬀects of BTC in this tissue were
not evident at the ages examined. Here, we report that BTC
transgenic (BTC-tg) mice develop a remarkably enlarged intes-
tine and increased crypt cell proliferation. Moreover, we em-
ployed the Egfrwa5 [20] and Apc+/Min [21] mouse models to
evaluate whether the phenotypical consequences of BTC over-
abundance are EGFR-dependent and whether increased levels
of BTC would alter the growth of adenomas in double mutant
mice.blished by Elsevier B.V. All rights reserved.
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2.1. Animals
Transgenic mice overexpressing BTC have been described previously
in detail [19]. Hemizygous BTC-tg mice from line 2 were mated to wild-
type (WT) FVB/N animals, the resulting litters were weaned at an age
of 3 weeks, and tail tips were used for genotyping by PCR. Egfrwa5
mice expressing an antimorphic Egfr allele [20] were donated by the
Medical Research Council (Oxfordshire, UK) via Dr. David Threadg-
ill (University of North Carolina, NC, USA). C57BL/6J-Apc+/Min mice
were purchased from the Jackson Laboratory.
The animals were maintained under speciﬁc pathogen-free condi-
tions in a closed barrier facility, and had free access to a standard ro-
dent diet (V1534, Ssniﬀ, Soest, Germany) and water. All experiments
were approved by the local veterinary authority and were carried out
according to the German Law of Animal Protection.
2.2. Tissue collection
Mice were killed by cervical dislocation and the gastrointestinal
tract was removed. After ﬂushing with ice-cold PBS, the small intes-
tine was cut into halves and the caecum and colon were separated.Fig. 1. Betacellulin overexpression causes phenotypical changes in the intes
month-old control animal and a transgenic littermate. (B) Hematoxylin–eo
intestine. (C) Periodic acid-Schiﬀ staining of small intestinal sections sho
hybridization showing increased BTC expression in transgenic tissue. (E) I
detection of BrdU incorporation in intestinal crypt cells. (G) Quantitative a
cells in BTC-tg mice as compared to gender-matched control littermates. A to
*P < 0.05.For routine histological evaluation, swiss-rolls [22] were prepared,
ﬁxed in 4% paraformaldehyde (PFA), dehydrated and embedded in
paraﬃn. Sections perpendicular to the plane of the tract were further
processed.
Mice in litters from BTC-tg vs. Apc+/Min matings were monitored
daily. Individual animals showed signs of illness at the age of 5
months and all animals were killed at this time point. Intestinal seg-
ments were cut longitudinally, laid open on Whatmann 3MM paper,
and ﬁxed overnight in 4% paraformaldehyde (PFA). After replacing
PFA with 70% ethanol, the number of polyps and their maximum
diameter were recorded under a dissection microscope at 10x magni-
ﬁcation.
2.3. Immunohistochemistry and in situ hybridization
A goat anti-betacellulin antibody was employed for spatial locali-
zation of the growth factor (R&D Systems, Wiesbaden, Germany).
For visualization of proliferating cells, mice were injected i.p. with
BrdU (30 mg/kg body weight) 2 h before killing. Proliferating cells
were detected with a rat anti-BrdU antibody (Oxford Biotechnology,
Kidlington, UK). In situ hybridization was carried out as described
[23].tine of transgenic mice. (A) Macroscopic view of the intestine of a 6-
sin staining demonstrating the increase in villus length in the small
wing normal number and distribution of Goblet cells. (D) In situ
mmunohistochemical localization of BTC. (F) Immunohistochemical
nalysis indicated a signiﬁcant increase in the number of BrdU-positive
tal of 40 mid-jejunal crypts per animal were counted (n = 2 mice/group).
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Western blots showing levels of caspase-3, cleaved caspase-3, or
GAPDH were carried out with 25 lg protein from the small intestinal
mucosa of BTC-tg or control mice. All antibodies and reagents were
obtained from Cell Signaling (Frankfurt, Germany).
2.5. Statistical analysis
Data are presented as means ± S.D. Groups were compared using
two-tailed Student t-tests and P < 0.05 was considered signiﬁcant.3. Results and discussion
3.1. Anatomical and histological changes elicited by BTC in the
intestine
Diﬀerences in intestinal size between WT and BTC-tg mice
became macroscopically visible at the age of 16 weeks and
increased further with age (Fig. 1A). Quantitative analysis
revealed that the small intestine of transgenic mice was
signiﬁcantly reduced in length and an increase in weight was
detected both in the small and large intestine (Table 1). Anal-
ysis of well-oriented histological sections from corresponding
regions (i.e. at identical distances from pyloric sphincter) of
intestinal rolls revealed a signiﬁcant increase in the length of
villi in BTC-tg mice as compared to WT animals (Table 1
and Fig. 1B). Evaluation of PAS-stained histological sections
showed a normal distribution of Goblet cells (Fig. 1C). In
addition, no changes in the distribution or localization of Pa-
neth cells were observed (data not shown), indicating normal
cell type distribution along the crypt-villus axis. Histological
evaluation of the intestinal epithelium of control and trans-
genic animals at diﬀerent ages (up to 12 months) did not reveal
pathological alterations such as ﬁbrosis, metaplastic or neo-
plastic lesions.
Although transgene-derived BTC expression in the intestine
was reported previously [19], no information was available
about its spatial localization. In situ hybridization revealed
considerably higher amounts of Btc message in the intestinal
epithelium of transgenic mice as compared to control animals
(Fig. 1D), and this was conﬁrmed for BTC protein by immu-
nohistochemistry (Fig. 1E).
3.2. BTC stimulates cell proliferation in the intestinal crypt
Immunohistochemical detection of BrdU incorporation re-
vealed a greatly expanded zone of labeled cells in the crypts
of transgenic mice (Fig. 1F) and quantitative analysis con-Table 1
Intestinal phenotype of BTC-tg mice and control littermates
Control Transgenic
Small intestine
Length (cm) 40.6 ± 2.4 33.7 ± 1.8**
Wet weight (g) 1.26 ± 0.11 2.00 ± 0.16***
Villus lengtha (lm) 204.5 ± 9.3 463.7 ± 2.6**
Large intestine
Length (cm) 7.7 ± 0.7 7.3 ± 0.6
Wet weight (g) 0.290 ± 0.03 0.352 ± 0.06*
Data shown are means ± S.D., n = 4 mice/group.
aCrypts in 10 mid-jejunal segments (0.5–0.7 mm each) were analyzed;
n = 2 animals per group.
*P < 0.05.
**P < 0.01.
***P < 0.001.ﬁrmed a signiﬁcantly higher number of BrdU-positive cells
per crypt in the transgenic group (Fig. 1G). This ﬁnding con-
trasts to the results obtained after the administration of recom-
binant BTC [18]. These disparate ﬁndings can have multiple
explanations, including the diﬀerent actions exerted by the
full-length, membrane-bound peptide (our studies) and the sol-
uble, mature peptide [18]; furthermore, our transgenic mice
have been exposed to higher-than-normal levels of BTC since
the embryonic development, while Howarth et al. [18] admin-
istered the peptide to adult animals and only for a limited
number of days. Finally, our ﬁnding of increased crypt cell
proliferation under a condition of increased EGFR ligand
availability is in accordance with the observation of reduced
proliferation in mice lacking the EGFR [4,5].
3.3. Eﬀects of BTC in the intestine are EGFR-dependent
Since BTC is also able to activate ERBB4 [24], we used a ge-
netic approach to evaluate to which extent the observed eﬀects
of BTC are mediated by the EGFR. Speciﬁcally, we crossed
BTC-tg mice to a mouse strain carrying the antimorphic allele
Egfrwa5, whose product acts as a dominant negative EGFR
[20]. At both macroscopic and histological levels, the intestinal
phenotype observed in BTC-tg animals was completely abro-
gated in double mutant mice (data not shown). Further, the
weight of small and large intestine of double mutant mice re-
turned to the levels observed in WT or Egfrwa5 animals
(Fig. 2) indicating that the phenotypical alterations observed
in the intestine of BTC-tg mice are to a great extent, if not
completely, a consequence of increased EGFR activation.
3.4. BTC overproduction increases the multiplicity of adenomas
in Apc+/Min mice
To test the potential involvement of BTC in tumor forma-
tion, we introduced the BTC transgene into mice carrying an
Apc+/Min allele, a widely used model of intestinal tumorigenesis
[21]. First signs of illness were apparent in some animals at the
age of 5 months. All mice were killed at this age and the total
number of polyps and their size were recorded. No polyps wereFig. 2. The phenotypical alterations observed in the intestine of BTC-
tg mice are EGFR-dependent. The weight of small (A) and large (B)
intestine of double mutant mice (BTC +Wa5) returned to the levels
observed in control or Egfrwa5 (Wa5) animals. All mice were
littermates and were analyzed at the age of 9 weeks (n = 3–5/genotype).
Values shown represent means ± S.D. *P < 0.05; **P < 0.01.
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BTC status (data not shown). While tumors were observed
in only approximately 60% of the Apc+/Min mice at 5 months,
100% of double mutant mice showed at least one polyp
(Fig. 3A). More importantly, BTC overproduction had a pro-
found eﬀect on the number of polyps arising in Apc+/Min mice
(Fig. 3B). In contrast to the increased polyp multiplicity, we
did not detect a signiﬁcant eﬀect of BTC on tumor size
(Fig. 3C). Representative polyps were excised including adja-
cent normal tissue and examined by a pathologist blinded to
the experimental group. No diﬀerences in the morphology
and the degree of dysplasia were observed (data not shown).
Increased BTC levels had no inﬂuence on the frequency of pol-
yps of the large intestine, which were observed only sporadi-
cally independently of the BTC status.
Since the number of polyps observed was rather low, we gen-
otyped the employed lines for Modiﬁer of Min 1 (Mom1) allele
status, an important modulator of polyp multiplicity [25].
Parental BTC-tg mice were found to be homozygous for the
resistant Mom1r allele, while Apc+/Min mice were homozygous
for the susceptible Mom1s allele (data not shown). Thus, F1
animals obtained from these crossings were 100% heterozy-
gous Mom1r/s (data not shown), providing an explanation
for the overall low polyp number.
Our ﬁndings are in contrast to the unchanged number of
intestinal polyps after EGF administration to Apc+/Min mice
[16]. However, these authors administered EGF over a rather
short period (4 weeks). In addition, the signaling pathways ini-
tiated by EGF or BTC are considerably distinct, with BTC
having a much more pronounced anti-apoptotic activity [26].Fig. 3. BTC overexpression in Apc+/Min mice increases adenoma multiplicity.
at least one adenoma. (B) Polyp number in the small intestine of Apc+/Min m
polyp number of an individual animal. The horizontal line represents the mea
is represented by a dot, while the horizontal line shows the mean for each geno
or GAPDH and quantitative analysis indicating a signiﬁcant decrease in the c
littermates.More importantly, our results are in line with the signiﬁcant
reduction in polyp multiplicity, but not in tumor size and qual-
ity due to decreased EGFR activity, as described in Apc+/Min
mice homozygous for the hypomorphic allele Egfrwa2 [15] or
carrying the antimorphic allele Egfrwa5 [20]. In the former re-
port [15], the authors proposed the concept that nascent tu-
mors – which are highly susceptible to being lost – require a
threshold level of EGFR activity to become established. Once
a certain growth stage has been reached, tumor survival can be
achieved by the already initiated downstream activity or by
parallel, EGFR-independent tumorigenic events. Our results
conﬁrm for the ﬁrst time an important prediction of this mod-
el, namely that increasing EGFR activity due to greater ligand
availability during this initial stage would increase ﬁnal polyp
number.
3.5. BTC has anti-apoptotic eﬀects on intestinal epithelial cells
Western blots carried out employing protein extracts from
the small intestine epithelium revealed markedly lower levels
of activated caspase-3 in samples from BTC-tg mice, as com-
pared to control mice (Fig. 3D). This result conﬁrms previous
observations indicating that BTC has stronger anti-apoptotic
actions as compared to EGF [26]. Furthermore, this ﬁnding
suggests that BTC overexpression creates an anti-apoptotic
environment in the gut epithelium, supporting the survival of
newly formed adenomas.
In summary, the present study uncovers a remarkable,
EGFR-dependent mitogenic eﬀect of BTC in the intestinal epi-
thelium. An additional important ﬁnding is the absence of
overt pathological (and specially neoplastic) alterations in(A) Percentage and absolute numbers of mice in both groups showing
ice with or without the BTC transgene. Each dot represents the total
n value of each genotype. (C) The mean polyp size in each single mouse
type. (D) Western blots showing levels of caspase-3, cleaved caspase-3,
leaved caspase-3/caspase-3 ratio in BTC-tg mice as compared to control
M. Dahlhoﬀ et al. / FEBS Letters 582 (2008) 2911–2915 2915the intestinal epithelium after long-term BTC excess in this tis-
sue, which suggest a potential therapeutical application of
these growth factor (or derivatives) for supporting cell prolif-
eration after gut resection or reparative processes after tissue
injury. The observed increase in polyp number after introduc-
tion of the BTC transgene into the Apc+/Min background is
most probably a general eﬀect of the EGFR as a ‘‘survival fac-
tor’’ for nascent adenomas.
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